Baiyang Pharmaceutical announced that Hebei Baiyang Sap Medical Equipment Technology Co., Ltd., a wholly-owned subsidiary of Baiyang Health Industry International Trading Co., Ltd., the company's wholly-owned subsidiary, plans to introduce Zap Therapeutic to increase its capital by 4.9 million US dollars. After the capital increase is completed, Baiyang SAP's registered capital will increase to 10 million US dollars, and Baiyang Health's shareholding ratio will drop to 51%. In order to expand the company's product layout in the field of innovative devices, since July 2024, the company has successively made industrial investments in ZapMedicalSystem, Ltd., and carried out a series of exclusive commercialization cooperation and manufacturing services for its core product, the ZAP-X Mars Boat radiosurgery robot. Zap Therapeutic's capital increase to BaiyangSap can fully integrate the various resource advantages of both parties, such as capital, technology, and market channels, which is conducive to promoting the localized production of ZAP-X and helping ZAP-X to quickly introduce clinical scenarios.

Zhitongcaijing · 11/19/2025 10:57
Baiyang Pharmaceutical announced that Hebei Baiyang Sap Medical Equipment Technology Co., Ltd., a wholly-owned subsidiary of Baiyang Health Industry International Trading Co., Ltd., the company's wholly-owned subsidiary, plans to introduce Zap Therapeutic to increase its capital by 4.9 million US dollars. After the capital increase is completed, Baiyang SAP's registered capital will increase to 10 million US dollars, and Baiyang Health's shareholding ratio will drop to 51%. In order to expand the company's product layout in the field of innovative devices, since July 2024, the company has successively made industrial investments in ZapMedicalSystem, Ltd., and carried out a series of exclusive commercialization cooperation and manufacturing services for its core product, the ZAP-X Mars Boat radiosurgery robot. Zap Therapeutic's capital increase to BaiyangSap can fully integrate the various resource advantages of both parties, such as capital, technology, and market channels, which is conducive to promoting the localized production of ZAP-X and helping ZAP-X to quickly introduce clinical scenarios.